|
Mergers and acquisitions have a way of looking clean from the outside. Companies front the big numbers, employees posting with confident messaging, and the PR team marketing a clear story about growth. But inside the business, it is rarely that simple. The real work begins after the deal closes, when two organizations are asked to become one. At a recent Square-1 Engineering Lunch and Learn, Achilles Young, Director of Business Process PMO for Global Operations and Supply Chain at Medtronic, shared what actually determines whether an acquisition delivers on its promise. His perspective came from more than 30 years in medical devices and, more importantly, from being deeply involved in the integration phase where most of the risk lives. Recent activity in Orange County reflects the tension that often surrounds these deals. Announcements are optimistic by nature. Leadership emphasizes growth, talent, and opportunity. But the market tends to react with more caution. When an acquiring company’s stock dips on news of a deal, it is rarely about the price tag alone. It signals concern about integration. Investors understand that combining systems, teams, and processes is where things can quietly unravel. That reality puts a spotlight on due diligence, which is often treated as a checkpoint rather than a true investigation. Financial and legal diligence tend to get the most attention, but operational diligence is where many of the most consequential risks sit. Achilles described what he calls the “hidden factory,” the gap between what is documented and what is actually happening on the floor. Processes evolve in practice. Workarounds emerge. Tribal knowledge fills in the blanks. None of that shows up neatly in SOPs, but all of it becomes critical during integration, especially in a regulated environment where undocumented activity must be validated and brought into compliance. Quality presents another layer of risk that is easy to underestimate. It is not enough to confirm that systems are compliant. The real question is whether they are stable. Trend data tells that story. Processes that hover near limits or show erratic performance may technically pass inspection, but they introduce fragility. Once integrated into a larger system, that instability has a way of surfacing quickly and at scale. Then there are the people. Expertise does not transfer automatically with an acquisition. The individuals who understand the nuances of a process, a piece of equipment, or a product are often the same ones who determine whether integration succeeds. Identifying those subject matter experts, capturing their knowledge, and ensuring they are aligned with the new organization is essential. Without that, critical insight can be lost at exactly the wrong time. If due diligence sets the foundation, synergies shape the expectations. It is a term that gets used often and understood loosely. In practice, synergies are not automatic. They require deliberate effort, realistic planning, and continuous adjustment. Achilles emphasized the importance of viewing outcomes across a range of scenarios rather than assuming a best-case trajectory. Timing plays a role here as well. Integration is not instantaneous, and pushing for immediate results can create more problems than it solves. Like any complex system, it requires the right sequencing and patience to come together effectively. Measurement becomes the mechanism that keeps everything grounded. Integration efforts rely heavily on KPIs, but not just high-level metrics. Surface indicators like output or defect rates only tell part of the story. The real value comes from understanding what is driving those numbers. If yield drops, the underlying causes matter. Contamination, testing failures, or process variation each require a different response. Strong integrations build visibility from the production floor up through leadership, creating alignment around what is happening and what needs attention. Leadership, however, is what ultimately determines whether that visibility translates into progress. Most organizations enter a deal with a clear integration strategy. Where they struggle is maintaining the discipline to execute it over time. Support from the executive team often fades after the initial push, just as the most challenging parts of integration begin. Teams are left navigating resource gaps, shifting priorities, and unexpected issues without the backing they need to stay on track. Sustained engagement from leadership helps protect momentum. It ensures that when problems arise, they are addressed quickly rather than allowed to compound. It also creates space to recognize progress, which is more important than it might seem. Integration is inherently disruptive. Small wins provide reassurance that the effort is working and that the team is moving in the right direction. Culture plays a central role in all of this, even if it is sometimes treated as secondary. When two organizations come together, they bring different ways of working, different assumptions, and different strengths. One may move quickly and prioritize innovation, while the other emphasizes structure and scale. The goal is not to eliminate those differences, but to understand and integrate them in a way that strengthens the combined organization. When done well, each side contributes something the other lacks. In the early stages of integration, priorities need to be clear. Financial alignment, quality systems, and regulatory compliance form the backbone of a stable transition. Core operational systems like ERP and standardized processes must be addressed quickly to avoid confusion and inefficiency. Other improvements can follow, but these foundational elements cannot be delayed. What becomes clear through all of this is that M&A is not simply a financial transaction. In the medical device industry, it is deeply operational and tightly connected to regulatory expectations. Success depends less on the deal itself and more on how effectively the organization navigates what comes next. Integration is where value is proven. And the organizations that approach it with clarity, discipline, and strong leadership are the ones that ultimately realize the opportunity they set out to capture. Looking for more support?
If you have questions about this topic or want to explore how our team can help with your MedTech project, contact us here. Want to see what we do? Visit our Services page or contact us directly to talk through your project and see if we’re the right fit.
0 Comments
Leave a Reply. |
About the AuthorTravis Smith is the founder and managing director of Square-1 Engineering, a medical device consulting firm, providing end to end engineering and compliance services. He successfully served the life sciences marketplace in SoCal for over 15 years and has been recognized as a ‘40 Under 40’ honoree by the Greater Irvine Chamber of Commerce as a top leader in Orange County, CA. |
RSS Feed